Patient eligibility and study design
breast cancer
ONCOLOGY, BREAST CANCER
This open label, randomized, parallel group, phase II trial was conducted at the Department of Oncology, Vejle Hospital, Denmark, and enrolled women with newly diagnosed, histologically verified breast cancer eligible for neoadjuvant treatment according to prevailing guidelines. The selection criteria are presented in Table Eligibility criteria for the NeoToc study.